Condition: Neurofibromatosis Type 1 · Sponsor: Healx Limited
The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.
This description comes directly from the study's public registry record.
Karen Cole-Plourde · (205) 934-5140 · kplourde@uab.edu
Lauren Baldwin · lahaynes@uabmc.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| New York University Langone Health | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06541847